17-α羟孕酮己酸酯对复发性早产高危孕妇妊娠延长的回顾性队列研究
本研究为2009至2019年单中心回顾性队列,纳入861例有自发早产史的单胎孕妇,其中152例(17.6%)发生<35周自发早产。Cox模型显示17-α羟孕酮己酸酯使用与妊娠延长至35周无关联(校正HR 0.83,95%CI 0.60-1.15)。
要点
- 在高危复发性早产孕妇中,17-α羟孕酮己酸酯未显示延长妊娠至35周。
- 队列风险特征与FDA批准该药的关键试验人群相似。
- 结果不支持该药在临床实践中降低复发性自发早产风险。
核心结论
- 在复发性自发早产高危孕妇的日常临床实践中,17-α羟孕酮己酸酯使用与妊娠延长至35周无关联。
研究设计与样本
- 回顾性队列研究,纳入2009至2019年学术三级中心单胎、有<37周自发早产史且妊娠超过16周的孕妇,排除历史指征宫颈环扎者。
主要发现
- 861例中570例(66.2%)为非西班牙裔黑人,237例(27.5%)居住在婴儿死亡率高(≥12.1/1000)的邮编区。
- 287例(33.3%)有超过1次自发早产史,372例(43.2%)既往自发早产≤32周,242例(28.1%)吸烟。
- 152例(17.6%)发生<35周自发早产,17-α羟孕酮己酸酯使用与妊娠延长无关联(校正HR 0.83,95%CI 0.60-1.15)。
临床怎么用
- 对于有自发早产史的高危孕妇,不应仅依据17-α羟孕酮己酸酯使用来预期延长妊娠至35周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of 17-α-hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth has become widespread, yet there are conflicting data regarding its efficacy. OBJECTIVE: We sought to determine whether administration of 17-α-hydroxyprogesterone caproate was associated with pregnancy prolongation in women at a high risk of recurrent spontaneous preterm birth. STUDY DESIGN: This is a retrospective cohort study of women with singleton pregnancies and a history of spontaneous preterm birth at <37 weeks' gestation who received care at our academic tertiary care center between 2009 and 2019. We included women with gestations that progressed beyond 16 weeks. We excluded those who underwent history-indicated cerclage placement. We first examined the characteristics of women who received 17-α-hydroxyprogesterone caproate and those who did not. Covariates with a P value of ≤.2 on this univariate analysis were considered for incorporation into a Cox proportional hazards model to assess the association between 17-α-hydroxyprogesterone caproate use and pregnancy prolongation up to 35 weeks. RESULTS: Of 861 women included in the study, 570 (66.2%) reported non-Hispanic black racial identity, 237 (27.5%) lived in zip codes with a high infant mortality rate (≥12.1/1000 infants), 287 (33.3%) had more than 1 previous spontaneous preterm birth, 372 (43.2%) had previous spontaneous preterm birth at ≤32 weeks' gestation, and 242 (28.1%) were smokers. Here, 152 pregnancies (17.6%) were complicated by spontaneous preterm birth at <35 weeks' gestation. Factors independently associated with pregnancy duration up to 35 weeks included weight gain of <0.2 kg (0.5 lb) per week, first recorded weight of <98 kg (215 lb), obstetrical history, non-Hispanic white racial identity, lack of prenatal care, and vaginal bleeding. Gestational age at delivery was also independently associated with interventions typically employed for midtrimester cervical shortening and/or dilation, including ultrasound- and examination-indicated cerclage, pessary placement, and vaginal progesterone administration. The use of 17-α-hydroxyprogesterone caproate was not associated with pregnancy prolongation (adjusted hazard ratio, 0.83; 95% confidence interval, 0.60-1.15). CONCLUSION: The risk profile of our cohort is similar to that of women enrolled in the landmark trial that led to the Food and Drug Administration's approval of 17-α-hydroxyprogesterone caproate. Despite the high-risk nature of the pregnancies examined, we found no association between use of the medication in daily clinical practice and pregnancy prolongation up to 35 weeks. This finding adds to the mounting evidence that calls into question the drug's efficacy in reducing the risk of recurrent spontaneous preterm birth.
引用
- Massa K, Childress K, Vricella LK, et al. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth. Am J Obstet Gynecol MFM. 2020. PMID: 33345927. doi:10.1016/j.ajogmf.2020.100219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。